WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006087557) METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/087557    International Application No.:    PCT/GB2006/000548
Publication Date: 24.08.2006 International Filing Date: 16.02.2006
IPC:
C07D 471/04 (2006.01), C07D 487/04 (2006.01), A61K 31/4985 (2006.01), A61P 29/00 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SY, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only).
ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB) (MG only).
ZABLUDOFF, Sonya [US/US]; (US) (For US Only).
BERGERON, Louise [CA/US]; (US) (For US Only)
Inventors: ZABLUDOFF, Sonya; (US).
BERGERON, Louise; (US)
Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca Ab, S-151 85 Södertälje (SE)
Priority Data:
60/654,131 18.02.2005 US
Title (EN) METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS
(FR) PROCEDE PERMETTANT DE DETERMINER LA SENSIBILITE A DES INHIBITEURS DE LA CHK1
Abstract: front page image
(EN)The invention is directed at a method for predicting a patient's responsiveness to a CHK1 inhibitor. The method includes providing a sample from a test patient who is being treated with a DNA damaging agent; and determining for the presence of an activated CHK1 signal transduction pathway molecule, wherein the presence of an activated CHK1 signal transduction pathway molecule is indicative that a CHK1 inhibitor should be administered to the patient.
(FR)L'invention concerne un procédé permettant de prévoir la sensibilité d'un patient à un inhibiteur de la CHK1. Ce procédé consiste à obtenir un prélèvement d'un patient d'essai traité à l'aide d'un agent endommageant l'ADN, puis à déterminer la présence d'une molécule de la voie de transduction du signal de la CHK1 activée, la présence d'une molécule de la voie de transduction du signal de la CHK1 activée indiquant qu'un inhibiteur de la CHK1 devrait être administré au patient.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)